Dr. Philippe Huot is a double-board certified movement disorder neurologist (Canada and the United States) and neuropharmacologist who endeavours to find new therapeutics to improve the lives of people with Parkinson’s disease (PD). To this end, his lab seeks to discover therapies to alleviate parkinsonian disability, L-DOPA-induced dyskinesia and dopaminergic psychosis. The approaches used encompass state-of-the art preclinical models of PD, as well as cutting-edge molecular biology techniques. Working with collaborators, Dr. Huot conducts pharmacological and imaging studies to better understand the mechanisms and targets involved in parkinsonism, dyskinesia and psychosis, as well as the interaction of novel drugs with these targets. Dr. Huot’s lab also aims to find disease-modifying therapies that could lead to a cure for PD through the development of preclinical models based on dissemination of pathological alpha-synuclein.